Home/Biosimilar Atlas/Companies/Fujifilm Kyowa Kirin Biologics

Fujifilm Kyowa Kirin Biologics

Biosimilar developer, Japan. 1 development product across 1 molecule: adalimumab.

First approval in the Atlas: Sep 2018, Hulio, adalimumab (EMA)
FDAproducts approved1
EMAproducts approved1
MHRAproducts approved1
PMDAproducts approved1
HCproducts approved1
CDSCOproducts approved0
EDEproducts registered1
Connections
1molecule1product6 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
AdalimumabHulio FKB327Jul 2020Sep 2018MHRAJun 2020Nov 2020ยทMay 20256/7

Month shown is the first approval or registration of that product in that market.

In development

ClinicalTrials.gov lists one comparative trial sponsored by Fujifilm Kyowa Kirin Biologics for one molecule: adalimumab. All of these candidates already have at least one approval in the seven markets.

MoleculeCandidateDeveloper or sponsorReference productPhaseDesignRegistry statusStartedPrimary completionIn the AtlasRegistry record
AdalimumabFKB327Fujifilm Kyowa Kirin BiologicsHumiraPhase 3Comparative efficacyCompletedJun 2015Jan 2018HulioNCT02405780

Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.

Companies on the same molecules

Developers whose portfolios overlap most with Fujifilm Kyowa Kirin Biologics, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

AlvotechOne shared molecule: adalimumab5 molecules in its portfolioAmgenOne shared molecule: adalimumab8 molecules in its portfolioBoehringer IngelheimOne shared molecule: adalimumab1 molecule in its portfolioCelltrionOne shared molecule: adalimumab10 molecules in its portfolioCoherus BioSciencesOne shared molecule: adalimumab2 molecules in its portfolioDaiichi SankyoOne shared molecule: adalimumab1 molecule in its portfolio

Chronology

Compare Fujifilm Kyowa Kirin Biologics with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.